109 related articles for article (PubMed ID: 27391058)
1. CDK4/6 inhibition: the late harvest cycle begins.
Goel S; Zhao JJ
Oncotarget; 2016 Aug; 7(31):48854-48856. PubMed ID: 27391058
[No Abstract] [Full Text] [Related]
2. The transcriptome of CDK4/6 inhibition.
Knudsen ES; Witkiewicz AK
Aging (Albany NY); 2017 Aug; 9(8):1859-1860. PubMed ID: 28860413
[No Abstract] [Full Text] [Related]
3. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
4. A New Cell-Cycle Target in Cancer - Inhibiting Cyclin D-Dependent Kinases 4 and 6.
Sherr CJ
N Engl J Med; 2016 Nov; 375(20):1920-1923. PubMed ID: 27959598
[No Abstract] [Full Text] [Related]
5. Unexpected outcomes of CDK4/6 inhibition.
Choi YJ; Sicinski P
Oncotarget; 2013 Feb; 4(2):176-7. PubMed ID: 23563596
[No Abstract] [Full Text] [Related]
6. CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest.
Goel S; DeCristo MJ; McAllister SS; Zhao JJ
Trends Cell Biol; 2018 Nov; 28(11):911-925. PubMed ID: 30061045
[TBL] [Abstract][Full Text] [Related]
7. Recent Advances of Cell-Cycle Inhibitor Therapies for Pediatric Cancer.
Mills CC; Kolb EA; Sampson VB
Cancer Res; 2017 Dec; 77(23):6489-6498. PubMed ID: 29097609
[TBL] [Abstract][Full Text] [Related]
8. The cyclin-dependent kinase 4/6 inhibitor, abemaciclib, exerts dose-dependent cytostatic and cytocidal effects and induces autophagy in multiple myeloma cells.
Iriyama N; Hino H; Moriya S; Hiramoto M; Hatta Y; Takei M; Miyazawa K
Leuk Lymphoma; 2018 Jun; 59(6):1439-1450. PubMed ID: 28918692
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition.
Álvarez-Fernández M; Malumbres M
Cancer Cell; 2020 Apr; 37(4):514-529. PubMed ID: 32289274
[TBL] [Abstract][Full Text] [Related]
10. The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies.
Knudsen ES; Witkiewicz AK
Trends Cancer; 2017 Jan; 3(1):39-55. PubMed ID: 28303264
[TBL] [Abstract][Full Text] [Related]
11. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
[TBL] [Abstract][Full Text] [Related]
12. The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival.
Wang H; Nicolay BN; Chick JM; Gao X; Geng Y; Ren H; Gao H; Yang G; Williams JA; Suski JM; Keibler MA; Sicinska E; Gerdemann U; Haining WN; Roberts TM; Polyak K; Gygi SP; Dyson NJ; Sicinski P
Nature; 2017 Jun; 546(7658):426-430. PubMed ID: 28607489
[TBL] [Abstract][Full Text] [Related]
13. Cyclin-dependent kinase 4/6 (cdk4/6) inhibitors: perspectives in cancer therapy and imaging.
Graf F; Mosch B; Koehler L; Bergmann R; Wuest F; Pietzsch J
Mini Rev Med Chem; 2010 Jun; 10(6):527-39. PubMed ID: 20370706
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulation by anticancer cell cycle inhibitors.
Petroni G; Formenti SC; Chen-Kiang S; Galluzzi L
Nat Rev Immunol; 2020 Nov; 20(11):669-679. PubMed ID: 32346095
[TBL] [Abstract][Full Text] [Related]
15. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
16. CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer.
Lim JS; Turner NC; Yap TA
Cancer Discov; 2016 Jul; 6(7):697-9. PubMed ID: 27371575
[TBL] [Abstract][Full Text] [Related]
17. Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor.
Freeman-Cook K; Hoffman RL; Miller N; Almaden J; Chionis J; Zhang Q; Eisele K; Liu C; Zhang C; Huser N; Nguyen L; Costa-Jones C; Niessen S; Carelli J; Lapek J; Weinrich SL; Wei P; McMillan E; Wilson E; Wang TS; McTigue M; Ferre RA; He YA; Ninkovic S; Behenna D; Tran KT; Sutton S; Nagata A; Ornelas MA; Kephart SE; Zehnder LR; Murray B; Xu M; Solowiej JE; Visswanathan R; Boras B; Looper D; Lee N; Bienkowska JR; Zhu Z; Kan Z; Ding Y; Mu XJ; Oderup C; Salek-Ardakani S; White MA; VanArsdale T; Dann SG
Cancer Cell; 2021 Oct; 39(10):1404-1421.e11. PubMed ID: 34520734
[TBL] [Abstract][Full Text] [Related]
18. Targeting cell-cycle machinery in cancer.
Suski JM; Braun M; Strmiska V; Sicinski P
Cancer Cell; 2021 Jun; 39(6):759-778. PubMed ID: 33891890
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
Patnaik A; Rosen LS; Tolaney SM; Tolcher AW; Goldman JW; Gandhi L; Papadopoulos KP; Beeram M; Rasco DW; Hilton JF; Nasir A; Beckmann RP; Schade AE; Fulford AD; Nguyen TS; Martinez R; Kulanthaivel P; Li LQ; Frenzel M; Cronier DM; Chan EM; Flaherty KT; Wen PY; Shapiro GI
Cancer Discov; 2016 Jul; 6(7):740-53. PubMed ID: 27217383
[TBL] [Abstract][Full Text] [Related]
20. CDK4/6 inhibition in early and metastatic breast cancer: A review.
de Groot AF; Kuijpers CJ; Kroep JR
Cancer Treat Rev; 2017 Nov; 60():130-138. PubMed ID: 28961554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]